Stay updated on Nivolumab in AML Remission at High Risk Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in AML Remission at High Risk Clinical Trial page.
Latest updates to the Nivolumab in AML Remission at High Risk Clinical Trial page
- Check7 days agoChange DetectedThe updates include adding a 'Locations' and 'Texas' label and removing the 'Texas Locations' header, and removing the HHS Vulnerability Disclosure footer link. These are minor labeling and navigation changes that do not affect study data, eligibility, or user actions.SummaryDifference0.2%
- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedRevision notice updated from v3.3.1 to v3.3.2 across the page footer, indicating a minor site update that does not affect study content or usability. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check35 days agoChange DetectedA new note clarifying that publications are automatically filled from PubMed and may not be about the study was added, and the footer revision label changed from v3.2.0 to v3.3.1.SummaryDifference0.1%
- Check43 days agoChange DetectedThe site-wide funding-status notice was removed; no core study information was altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check57 days agoChange DetectedUpdated the Study Details page to include results-related sections and new timing information. Dates for enrollment, primary completion, and study completion have been updated.SummaryDifference0.4%
- Check86 days agoChange DetectedThe page now includes a government-funding lapse notice and a new v3.2.0 update, replacing the old v3.1.0 tag.SummaryDifference3%
Stay in the know with updates to Nivolumab in AML Remission at High Risk Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in AML Remission at High Risk Clinical Trial page.